Clavis Pharma appoints Nicholas Adams as Chief Business Officer

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, is pleased to announce the appointment of Nicholas Adams as Chief Business Officer. He replaces Jan Alfheim, who has taken up the position of Managing Director at Nordic Nanovector AS.

Mr Adams has more than 23 years of experience in the healthcare industry. For the past 12 years, he worked for the UK-quoted cancer company Antisoma plc, the majority of which as Vice President Business Development and a member of the senior management team. During his time at Antisoma, Mr Adams gained experience across a range of international deal types (including in- and out-licensing, divestments, royalty buy-outs and M&A).

Prior to this, Mr Adams spent eleven years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance. He has a degree in biology from the University of Hertfordshire and postgraduate qualifications in law from the College of Law in London.

Olav Hellebø, Clavis Pharma CEO, commented: “We are very pleased to welcome Nick to the management team at Clavis Pharma, as he brings to the company his considerable experience in business development particularly in the creation of partnerships with leading pharmaceutical companies, and with a strong focus in oncology. This experience will prove to be very important as we increasingly leverage the partnering opportunities for our unique pipeline of novel cancer therapeutics. We also thank Jan for his contribution to Clavis Pharma over the past 4 years and wish him well in his new role. ”

Nicholas Adams has been awarded 100,000 share options in Clavis Pharma. The share options have a strike price of NOK 46,80 equal to the closing trading price of the shares on the last trading day prior to commencing employment. Following the grant Mr Adams holds 100,000 share options in the company. The options expire after 10 years, conditional upon continued employment, and vest with ¼ each year for the first 4 years.